ciprofloxacin

Ciprofloxacin (Bay-09867), a synthetic broad spectrum fluoroquinolone antibiotic, inhibits bacterial DNA gyrase. It is more active against Gram-negative bacteria than Gram-positive bacteria.

Ciprofloxacin monohydrochloride (Bay-09867 hydrochloride) is a broad-spectrum antimicrobial carboxyfluoroquinoline.

Ciprofloxacin EP IMpurity A (Fluoroquinolonic Acid) is an antibiotic and antimicrobial agent.

Ciprofloxacin hydrochloride monohydrate (Bay-09867 hydrochloride monohydrate) is a fluoroquinolone antibiotic,is an antibiotic used to treat a number of bacterial infections

Desethylene ciprofloxacin is a major metabolite of ciprofloxacin . It is also a degradation product of ciprofloxacin that can be created through advanced oxygenation processes as a potential way to remove ciprofloxacin from wastewater. It is also created during degradation of ciprofloxacin by chlorination.

Ciprofloxacin lactate is a useful organic compound for research related to life sciences. The catalog number is T66299 and the CAS number is 97867-33-9.

Ciprofloxacin-d8 is a deuterated compound of Ciprofloxacin. Ciprofloxacin has a CAS number of 85721-33-1. Ciprofloxacin, a synthetic broad spectrum fluoroquinolone antibiotic, inhibits bacterial DNA gyrase. It is more active against Gram-negative bacteria than Gram-positive bacteria.

Ciprofloxacin-d8 Hydrochloride is a deuterated compound of Ciprofloxacin Hydrochloride. Ciprofloxacin Hydrochloride has a CAS number of 93107-08-5. Ciprofloxacin hydrochloride is a broad-spectrum antimicrobial carboxyfluoroquinoline.

n-acetylciprofloxacin (3-Quinolinecarboxylic acid, 7-(4-acetyl-1-piperazinyl)-1-cyclopropyl-6-fluoro-1) is inhibitor of H37Rv.

Antibacterialagent 254 (Compound 2) is an antimicrobial agent capable of eradicating 7-day-old P. aeruginosa biofilms at a concentration of 50 μM without affecting bacterial growth. Additionally, Antibacterialagent 254 enhances the efficacy of Ciprofloxacin against P. aeruginosa and upregulates the expression of the matrix-degrading enzyme genes pelA, pslG, and eddA.

BV600022 is an osteoadsorptive bisphosphonate-ciprofloxacin conjugate with antibacterial activity.

PD 117588 is a quinolone against bacterial isolates from cancer patients. PD 117558 has a broad antimicrobial spectrum with excellent activity against all Gram-positive isolates (including methicillin-resistant Staphylococcus aureus, coagulase-negative st

Ro 24-6392 is an ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime. Ro 24-6392 demonstrats activity against a wide spectrum of aerobic bacteria.

ABT-719 is a 2-pyridinone antimicrobial agent that is more effective against Enterococcus faecalis strains than ciprofloxacin and vancomycin, which showed resistance to ciprofloxacin and vancomycin covering a range of MIC.

IMP-1700 is an inhibitor of bacterial DNA repair.1It potentiates the activity of the quinolone antibiotic ciprofloxacin against methicillin-resistantS. aureus(MRSA) with a combination index value of 0.7. IMP-1700 inhibits the ciprofloxacin-induced bacterial SOS response, a process that repairs DNA damage, in a reporter assay in a concentration-dependent manner. It is also active againstE. coli, as well as methicillin-resistant and -sensitive S. aureus, when used alone (EC50s = 0.5, 0.21, and 3.8 μM, respectively). 1.Lim, C.S.Q., Ha, K.P., Clarke, R.S., et al.Identification of a potent small-molecule inhibitor of bacterial DNA repair that potentiates quinolone antibiotic activity in methicillin-resistant Staphylococcus aureusBioorg. Med. Chem.27(20)114962(2019)

Antifungal agent 16 has antimicrobial activity comparable to that of ciprofloxacin and has higher antifungal activity than fluconazole.

Anticancer agent 67 is a ciprofloxacin analogue, an anticancer agent that induces apoptosis and increases sub-G1 cell populations in MCF-7 cells.

Piperazine (2HCl) is gamma-aminobutyric acid (GABA) agonists and its major effects appear to be on the central nervous system. Piperazine was the anthelmintic with the greatest number of reports of toxicoses and suspected toxicoses in cats. Piperazine neurotoxicity in cats and dogs usually was manifested by muscle tremors, ataxia, and or behavioral disturbances within 24 hours after estimated daily dose(s) between 20 and 110 mg kg[1]. For di-substituted derivatives, ciprofloxacin was selected and hybrids were synthesized via substitution at piperazinyl-N4. The reaction of piperazinyl-NH of ciprofloxacin with selected drugs resulted in pronounced growth inhibition of standard as well as resistant bacterial strains[2]. The parent piperazine 6 was found to exhibit a reasonable activity toward the HeLa and MDA MB 231 tumor cell lines (IC50= 9.2 and 8.4 μΜ, respectively)[3]. Piperazine adipate (10 mM) causes mortality of A. galli and H. gallinae after a maximum of 30 min exposure, inhibits malate oxidation by 78%, and inhibits aldolase activity in both parasites. Piperazine adipate (10 mM) also inhibits cholinesterase activity by 96% in Ascaridia galli (A. galli) and 93% in Heterakis gallinae (H. gallinae). Piperazine adipate inhibits oxaloacetate reduction by 26% and 55% in A. galli and H. gallinae, resepctively[4].

Anticancer agent 66, a ciprofloxacin analog, functions as an anti-cancer agent by inducing apoptosis and elevating the sub-G1 cell population in MCF-7 cells.

Antibacterial Agent 128, a siderophore analog-Ciprofloxacin (Ciprofloxacin) conjugate connected via a cleavable linker, demonstrates effective antibiotic properties. Specifically, it exhibits activity against P. aeruginosa and B. pseudomallei, with Minimum Inhibitory Concentration (MIC) values ranging from 0.25 to 64 μg mL and 1 to 32 μg mL, respectively [1].

Pazufloxacin (T-3761) is a fluoroquinolone antibiotic used for antibacterial applications. This novel quinolone derivative exhibits robust and broad-spectrum antibacterial efficacy against systemic, pulmonary, and urinary tract infections in mice, effectively targeting both gram-positive and gram-negative bacteria, including quinolone-resistant strains such as Serratia marcescens and Pseudomonas aeruginosa. Compared to antibiotics like ofloxacin, ciprofloxacin, norfloxacin, and tosufloxacin, Pazufloxacin demonstrates comparable or superior efficacy across various infection models. While slightly less effective than tosufloxacin against certain gram-positive infections, it remains potent against methicillin-resistant Staphylococcus aureus. Its broad-spectrum activity is supported by minimum inhibitory concentrations (MICs) between 0.39 and 6.25 micrograms ml for Staphylococcus aureus and Clostridium species, with minimum bactericidal concentrations (MBCs) close to the MICs. Additionally, its 50% inhibitory concentrations for DNA gyrases from E. coli and P. aeruginosa are 0.88 and 1.9 micrograms ml respectively, highlighting its potent antibacterial mechanism of action.

BO-1, a benzoate ester, exhibits antibacterial properties, effectively inhibiting multidrug-resistant Staphylococcus aureus. It synergizes with antibiotics like Ciprofloxacin, reversing resistance in antibiotic-resistant S. aureus strains. Additionally, BO-1 reduces the levels of inflammatory factors IL-6 and C-reactive protein in vivo in mice [1].

Quorum Sensing-IN-2 (compound 23e) is a quorum sensing inhibitor that reduces bacterial pathogenicity without affecting growth, exhibits minimal hemolytic activity, effectively inhibits bacterial infections, and shows a synergistic effect when combined with Ciprofloxacin in a P. aeruginosa PAO1-infected bacteremia model [1].

Anticancer Agent 118, an N‑acylated ciprofloxacin derivative, exhibits antibacterial efficacy against Gram-positive strains and antiproliferative effects on prostate PC3 cells, making it a potential candidate for antitumor research [1].